Haemonetics Corporation (HAE)

BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ®  Plasma Collection System with Persona ®  PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.

BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N.

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1 Based on robust, high-quality evidence, including clinical trial data demonstrating con.

The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance Group Ltd, Revolve Group Inc. and Haemonetics Corporation. Detractors from relative performance were NewMarket Corporation, Certara, Inc. and Gates Industrial Corporation plc.

RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026.

Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time Pivotal Phase 3 data from RAPIDe-3 of deucrictibant for the on-demand treatment of HAE attacks to be presented for the first time

Exploring the Fourth Quarter 2025 13F Filing Chuck Royce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, providing insigh

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Haemonetics (NYSE: HAE) management struck an upbeat tone on its fiscal third-quarter 2026 earnings call, highlighting "outsized" growth in its NexSys plasma platform and TEG hospital blood management franchise, while acknowledging continued weakness in Interventional Technologies. The company reported third-quarter revenue of $339 million and raised full-year revenue, earnings, and free cash flow guidance, citing sustained

Haemonetics Corporation (NYSE: HAE) reported upbeat earnings for its third quarter on Thursday.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

HAE beats Q3 EPS and revenue estimates as margins expand sharply, but sales fall 2.7% year over year, sending shares down after the report.

Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript

Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but market adoption hinges on Phase 3 results.

While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.